Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors.

The development of potent, orally bioavailable, and selective series of 5-amino-3-hydroxy-N(1-hydroxypropane-2-yl)isothiazole-4-carboxamidine inhibitors of MEK1 and MEK-2 kinase is described. Optimization of the carboxamidine and the phenoxyaniline group led to the identification of 55 which gave good potency as in vitro MEK1 inhibitors, and good oral exposure in rat.

[1]  G. Nuovo,et al.  Hyperexpression of mitogen-activated protein kinase in human breast cancer. , 1997, The Journal of clinical investigation.

[2]  Alexander Levitzki,et al.  Signal-transduction therapy , 1994 .

[3]  D. Powell,et al.  Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[4]  M. Hidalgo,et al.  Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). , 2003, Advances in experimental medicine and biology.

[5]  S. Frantz.  Drug discovery: Playing dirty , 2005, Nature.

[6]  J. Wityak,et al.  MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. , 1998, Bioorganic & medicinal chemistry letters.

[7]  M. Poss,et al.  Pyrrolopyridazine MEK inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[8]  J. Wityak,et al.  Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[9]  I. Smith,et al.  The development and clinical use of trastuzumab (Herceptin). , 2002, Endocrine-related cancer.

[10]  W. Kolch.  Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. , 2000, The Biochemical journal.

[11]  D. Powell,et al.  MEK (MAPKK) inhibitors. Part 2: structure-activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolines. , 2001, Bioorganic & medicinal chemistry letters.

[12]  S. Chaudhuri,et al.  Differential regulation of the protein tyrosine kinase activity followingiInterleukin-2 (IL-2), Interferron gamma (IFN?) and SRBC administration in brain tumor induced conditions: SRBC acting as a dual potentiator in regulating the cytokine profile , 2004, Cancer biology & therapy.

[13]  Yi Liu,et al.  Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[14]  C. Varaprasad,et al.  Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[15]  D. Boschelli,et al.  Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade. , 2003, Bioorganic & medicinal chemistry letters.

[16]  A. Bridges,et al.  A synthetic inhibitor of the mitogen-activated protein kinase cascade. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[18]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[19]  D. Berger,et al.  Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase. , 2004, Molecular cancer therapeutics.

[20]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[21]  E. Krebs,et al.  The MAPK signaling cascade , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  M. Cobb,et al.  Mitogen-activated protein kinase pathways. , 1997, Current opinion in cell biology.

[23]  J. Lyssikatos,et al.  Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. , 2005, Current topics in medicinal chemistry.